share_log

Wedbush Reiterates Outperform on Artiva Biotherapeutics, Maintains $18 Price Target

Benzinga ·  Mar 25 14:16

Wedbush analyst Martin Fan reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Outperform and maintains $18 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 305

Recommended

Write a comment